Skip to main content

Ligands for Surface Receptors

  • Reference work entry
Drug Design
  • 5318 Accesses

Abstract

In Chap. 29, “Agonists and Antagonists of Membrane-Bound Receptors,” receptors were discussed that allow a signal transmission from outside the cell to its interior. Numerous processes in the cell are initiated by these systems that alter the cell’s state. In addition to this type of information exchange, a cell must also have other ways to remain constantly in contact with its environment. To accomplish this task, they have many other surface receptors. For example, the cell’s integrin receptor not only can accept signals from outside, it can also transmit signals into the environment. If a cell moves, for example in a blood vessel or in tissue, it must remain in constant communication with the environment during the translocation. In this way, leukocytes find their way to sites of infection as part of immune response to pathogens. For this, they receive signals from the environment through their surfaces by using special surface receptors. In viral disease, a virus attempts to adhere to a host cell and finally to penetrate the cell. The recognition of endogenous cell-surface receptors or special adhesion molecules initially occurs before the target cell under attack can be reprogrammed in the invasion process. After viral maturation and reproduction, the new virus must be budded and released from the infected host cell (exocytosis). Proteins that are exposed to the surface also regulate this process. Drugs can be used to intervene in both processes: the attack by and release of viruses. Our immune system uses specific surface proteins to distinguish between diseased and healthy cells. Influencing these processes leads to immune stimulation. The structure and function of the above-mentioned surface receptors shall be discussed in this chapter. How specific ligands can suppress or reprogram the actual tasks of these surface receptors to lead to a successful therapeutic concept shall be explained.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 649.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 949.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Bibliography

General Literature

  • Andronati SA, Karaseva TL, Krysko AA (2004) Peptidomimetics– antagonists of the fibrinogen receptors: molecular design, structures, properties and therapeutic applications. Curr Med Chem 11:1183–1211

    Article  PubMed  CAS  Google Scholar 

  • Chhabra SR, Abdul Rahim AS, Kellam B (2003) Recent progress in the design of selectin inhibitors. Mini Rev Med Chem 3:679–687

    Article  PubMed  CAS  Google Scholar 

  • De Palma AM, Vliegen I, De Clercq E, Neyts J (2008) Selective inhibitors of picornavirus replication. Med Res Rev 28:823–884

    Article  PubMed  Google Scholar 

  • Doranz BJ, Baik SW, Doms RW (1999) Use of a gp120 binding assay to dissect the requirements and kinetics of human immunodeficiency virus fusion events. J Virol 12:10346–10358

    Google Scholar 

  • Kolata G (2001) The story of the great influenza pandemic of 1918 and the search for the virus that caused it. Touchstone, New York

    Google Scholar 

  • Lazoura E, Apostolopoulos V (2005) Rational peptide-based vaccine design for cancer immunotherapeutic applications. Curr Med Chem 12:629–639

    Article  PubMed  CAS  Google Scholar 

  • Matthews T, Salgo M et al (2004) Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov 3:215–225

    Article  PubMed  CAS  Google Scholar 

  • Shimaoka M, Springer TA (2003) Therapeutic antagonists and conformational regulation of integrin function. Nat Rev Drug Discov 2:703–716

    Article  PubMed  CAS  Google Scholar 

  • Somers WS, Tang J, Shaw GD, Camphausen RT (2000) Insights into the molecular basis of leukocyte tethering and rolling revealed by structures of P- and E-selectin bound to SLeX and PSGL-1. Cell 103:467–479

    Article  PubMed  CAS  Google Scholar 

  • von Itzstein M (2007) The war against influenza: discovery and development of sialidase inhibitors. Nat Rev Drug Discov 6:967–974

    Article  Google Scholar 

Special Literature

  • Douat-Casassus C, Marchand-Geneste N, Diez E, Gervois N, Jotereau F, Quideau S (2007) Synthetic anticancer vaccine candidates: rational design of antigenic peptide mimetics that activate tumor-specific T-cells. J Med Chem 50:1598–1609

    Article  PubMed  CAS  Google Scholar 

  • Garboczi DN et al (1996) Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 384:134–141

    Article  PubMed  CAS  Google Scholar 

  • Jiang S, Zhao Q, Debnath AK (2002) Peptide and non-peptide HIV fusion inhibitors. Curr Pharm Des 8:563–580

    Article  PubMed  CAS  Google Scholar 

  • Kim CU, Lew W et al (1997) Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 119:681–690

    Article  PubMed  CAS  Google Scholar 

  • Kim CU, Lew W et al (1998) Structure–activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors. J Med Chem 41:2451–2460

    Article  PubMed  CAS  Google Scholar 

  • Kolatkar PR et al (1999) Structural studies of two rhinovirus serotypes complexed with fragments of their cellular receptor. EMBO J 18:6249–6259

    Article  PubMed  CAS  Google Scholar 

  • Kranich R, Busemann AS et al (2007) Rational design of novel, potent small molecule pan-selectin antagonists. J Med Chem 50:1101–1115

    Article  PubMed  CAS  Google Scholar 

  • Ku TW, Ali FE, Barton LS et al (1993) Direct design of a potent non-peptide fibrinogen receptor antagonist based on the structure and conformation of a highly constrained cyclic RGD peptide. J Am Chem Soc 115:8861–8862

    Article  CAS  Google Scholar 

  • Smith PW, Sollis SL et al (1996) Novel inhibitors of influenza silaidases related to GGI67. Bioorg Med Chem Lett 6:2931–2936

    Article  CAS  Google Scholar 

  • Williams MA, Lew W et al (1997) Structure–activity relationships of carbocyclic influenza neuraminidase inhibitors. Bioorg Med Chem Lett 7:1837–1842

    Article  CAS  Google Scholar 

  • Zablocki JA, Rico JG, Garland RB, Zablocki JA, Rico JG, Garland RB et al (1995) Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp sequence of fibrinogen. (Aminobenzamidino)succinyl (ABAS) series of orally active fibrinogen receptor antagonists. J Med Chem 38:2378–2394

    Article  PubMed  CAS  Google Scholar 

  • Zhang Y et al (2004) Structural and virological studies of the stages of virus replication that are affected by antirhinovirus compounds. J Virol 78:11061–11069

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Berlin Heidelberg

About this entry

Cite this entry

Klebe, G. (2013). Ligands for Surface Receptors. In: Klebe, G. (eds) Drug Design. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-17907-5_31

Download citation

Publish with us

Policies and ethics